Clinical Psychiatry

Intermittent explosive disorder (IED)

ICD-10F63.8Other habit and impulse disorders
DSM-5-TRF63.81Intermittent Explosive Disorder

1. Definition and nosology

Intermittent Explosive Disorder (IED; ICD-11: 6C73 Intermittent Explosive Disorder; DSM-5-TR: F63.81) — recurrent, uncontrolled verbal or physical aggressive outbursts; disproportionately intense relative to triggering provocation. Remorse or shame follows the act.

2. History

  1. DSM-III (1980) — Official diagnosis of IED.
  2. DSM-5 (2013) — criteria refined.
  3. ICD-11 (2019) — under impulse control disorders.

3. Epidemiology

  • Lifetime prevalence: 4–7% (Kessler R.C. et al. Arch Gen Psychiatry 2006).
  • Sex: higher in males.
  • Onset: mid-adolescence.
  • Comorbidity: MDD ~70%, anxiety, substance use, BPD, ASPD.

4. Etiology and pathogenesis

  • Heritability 40%.
  • Serotonin dysregulation — SSRI effect.
  • Trauma and abuse history.
  • Disruption of cortex-amygdala regulation.

5. Clinical features

  • Recurrent aggressive outbursts — verbal (screaming, threats) or physical (object damage, harm to others).
  • Explosion out of control — the patient is unable to restrain it.
  • The trigger is minimal or minor.
  • Post-act remorse, shame, guilt.
  • Relationship, work, legal consequences.

6. Diagnosis

6.1 Unified diagnostic criteria

A. One of the following:

  • Verbal or physical aggressive outbursts, without destructive harm, ≥2 times per week, ≥3 months.
  • Three or more disruptive/damaging outbursts within a 12-month period.

B. Aggression disproportionate to the trigger.

C. Outbursts are impulsive (not planned), not for a specific purpose.

D. Significant distress or functional impairment.

E. Chronological age ≥ 6 years.

F. Not better explained by another mental disorder (manic, ASPD, BPD, conduct disorder); rule out substance effects.

6.2 Differences between sources

  1. DSM-5-TR — criterion A1 (mild) and A2 (destructive) separately.
  2. ICD-11 sets no frequency or age threshold; DSM-5-TR requires the A1/A2 split, twice weekly for three months or three destructive outbursts in 12 months, and age ≥6; ICD-11 sets none of these.

6.3 Diagnostic algorithm

  • Clinical interview + family information.
  • Scale — OAS (Overt Aggression Scale), BPAQ (Buss-Perry Aggression Questionnaire).
  • Comorbidity and exclusion of medical causes (frontal lobe injury, epilepsy, hypoglycemia).
  • Toxicology.

6.4 Differential diagnosis

Condition Distinguishing feature
ASPD (Antisocial) Planned aggression, no regret.
BPD Emotional lability and relationships central.
Manic episode In the context of an affective episode.
Conduct-dissocial disorder (6C91) Multiple instances of antisocial behavior.
ODD (6C90) Persistent oppositional component with aggression, but outbursts are not primary.
Frontal lobe pathology Neurological.
Substance-induced aggression Toxicology.

7. Examination and assessment

  1. OAS, BPAQ.
  2. Medical and neurological.
  3. Toxicology.
  4. Comorbidity scales.

8. Treatment

  • Fluoxetine (SSRI) — Coccaro E.F. et al. J Clin Psychiatry 2009 RCT — most evidence-based pharmacotherapy in IED; 20–60 mg/day.
  • CBT — anger management, cognitive restructuring, behavioral activation, relaxation. McCloskey M.S. et al. J Consult Clin Psychol 2008.
  • Mood stabilizers — valproate, lithium (off-label in refractory cases).
  • Comorbid disorder treatment.
  • Legal coordination when needed.

8.1 Treatment methods

  1. Fluoxetine — SSRI; evidence base from Coccaro RCT in IED.
  2. CBT for anger management — trigger identification, cognitive restructuring, time-out, relaxation, problem-solving.
  3. Overt Aggression Scale (OAS) — Aggression Scale.

8.2 Differences between sources

  1. Coccaro J Clin Psychiatry 2009 — fluoxetine evidence-based.
  2. McCloskey 2008 — CBT efficacy.

9. Prognosis

  • Significant improvement with fluoxetine and CBT.
  • Comorbid ASPD, substance use poor prognosis.

10. Myths and misconceptions

Myth 1: “IED is just ordinary ‘temper tantrum’”

Evidence: Clinical diagnosis based on frequency and functional impairment.

Myth 2: “The patient can stop ‘voluntarily’”

Evidence: impulse control disorder — failure of control is clinical feature; evidence-based treatment (fluoxetine, CBT) required.

Myth 3: “Benzodiazepine calms aggression”

Evidence: benzodiazepine paradoxical disinhibition can occur; contraindicated or used cautiously in IED.

Myth 4: “Only legal punishment is effective”

Evidence: legal punishment alone ineffective; clinical treatment required.

Myth 5: “Antipsychotic is first-line”

Evidence: SSRI first-line; antipsychotics in refractory cases.

11. Sources

  • WHO. ICD-11. 6C73 Intermittent explosive disorder. 2024.
  • APA. DSM-5-TR. 2022.
  • Coccaro E.F. et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009;70(5):653–662.
  • McCloskey M.S. et al. Cognitive-behavioral therapy for intermittent explosive disorder. J Consult Clin Psychol 2008;76(5):876–886.
  • Kessler R.C. et al. The prevalence and correlates of DSM-IV intermittent explosive disorder. Arch Gen Psychiatry 2006;63(6):669–678.